Publication:
Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report.

Thumbnail Image
Identifiers
URI: http://hdl.handle.net/20.500.12105/18615
ISSN: 1664-2392
DOI: 10.3389/fendo.2022.838887
Full text access: http://hdl.handle.net/10668/20559

Publication date

2022-04-14

Authors

Advisors

Journal Title

Journal ISSN

Volume Title

Publishers

Metrics
Google Scholar
Export
MarcXML METS

Research Projects

Organizational Units

Journal Issue

Abstract

Type A insulin resistance (IR) syndrome is a very uncommon genetic disorder affecting the insulin receptor (INSR) gene, characterized by severe IR without the presence of obesity. Patients with this condition will eventually develop diabetes, presenting a variable response to insulin-sensitizers, such as metformin and thiazolidinediones, and high doses of insulin. We report for the first time the results of the use of combination therapy with a glucagon-like peptide-1 receptor agonist and a sodium-glucose cotransporter 2 inhibitor for the treatment of diabetes in the context of type A IR syndrome.

Description

Keywords

Type A insulin resistance syndrome diabetes glucagon-like peptide-1 receptor agonist insulin resistance sodium-glucose cotransporter 2 inhibitor

MeSH Terms

Benzhydryl Compounds Diabetes Mellitus Glucagon-Like Peptides Glucosides Humans Insulin Insulin Resistance

DeCS Terms

Bibliographic citation

Collections

IBIMA-Plataforma BIONAND - Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (Andalucía)

Publisher version

Related dataset

Related publication

Document type

research article